Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma.

Abstract

This phase II study was performed to determine the induction of a specific T-cell response, the clinical response rate, and toxicity of vaccination with different HLA class I-binding peptide epitopes derived from the melanocyte differentiation antigen tyrosinase in patients with stage IV melanoma. The study population consisted of 16 patients with… (More)

Topics

Cite this paper

@article{Scheibenbogen2000Phase2T, title={Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma.}, author={Carmen Scheibenbogen and Alexander Schmittel and Ulrich Keilholz and T Allg{\"a}uer and U. Hofmann and Roman Max and Eckhard Thiel and Dirk Schadendorf}, journal={Journal of immunotherapy}, year={2000}, volume={23 2}, pages={275-81} }